01 — Restrain
Restrain
We identify the regulatory drivers of fibrosis and pathological signaling, then engineer precision brakes to halt disease at its source.
Anti-fibrotic · signal control
A computational discovery platform that identifies the regulatory switches biology uses to restrain disease — then designs therapeutics that restore those brakes when disease overrides them.
At the root of progressive disease lies a moment where biology's natural restraint fails. Frena restores that restraint, then carries tissue back toward health.
We identify the regulatory drivers of fibrosis and pathological signaling, then engineer precision brakes to halt disease at its source.
With disease arrested, we target the damaged matrix and cellular machinery — restoring the structures that injury and scarring have degraded.
Beyond stabilization, our targets reactivate the body's own regenerative programs — guiding tissue back toward healthy, functional architecture.
Frena's discovery engine integrates computational genomics, AI-driven target prioritization, and modality-agnostic drug design to identify and engineer molecular brakes on disease.
We validate targets through human genetic causal inference — including Mendelian randomization across population-scale datasets — to ensure the switches we modulate are driving disease, not merely correlated with it. From there, we design precision therapeutics across small-molecule, antisense, and biologic modalities, matched to each target's biology and tissue context.
The same fibrotic and regulatory machinery drives disease across organs — letting one platform reach many indications.
Targeting the acute-to-chronic transition — where loss of regenerative signaling and gain of fibrotic regulators drive millions toward end-stage renal disease.
Restraining the proliferative and matrix-remodeling programs that let tumors progress, evade, and metastasize.
Re-engaging the molecular brakes that resolve immune escalation and prevent chronic inflammatory damage.